Northrop Grumman’s Record Backlog Doesn’t Move the Tape – Two Program Hiccups Mask an Accelerating Core
The Divergence
Northrop Grumman's second-quarter earnings were objectively strong: net awards of $20 billion, a 1.84x book-to-bill, a 17% jump in backlog to $105 billion, and a raised full-year sales guide to $44 billion at the midpoint. CFO John Greene was matter-of-fact: “Second quarter awards totaled $20 billion, driving backlog up 17% year over year to $105 billion.” — John Thomas Greene, Corporate Vice President and Chief Financial Officer · 2026-07-21 CEO Kathy Warden opened the call with a clear signal: “We are fully aligned with the US government priorities and see significant opportunity and increased demand for our portfolio.” — Kathy J. Warden, Chair, CEO and President · 2026-07-21 Yet the stock sits 28% below its March peak and has shed 18% over the last 90 days. The market is focused on two negative EAC adjustments – GEM 63XL in Space and the Stand-in Attack Weapon (SAW) in Defense Systems – and wondering if these are isolated or symptoms of a broader margin problem.
Two Blemishes, Not a Broken Model
These EACs are real but manageable. On GEM 63XL, the company completed a static fire test and expects to ship redesigned motors by year-end. On SAW, the increase in projected cost is tied to qualification testing delays, but the program remains strategically important – it is part of a tactical missile growth strategy with billions of potential sales. Warden was direct:
Excluding these two items, the company's segment margins would have been in the high-11% range – a level the CFO called out as evidence that the core business is humming. The EAC adjustment on GEM 63XL is a one-time fix, not a recurring theme; the Attack Weapon investment is a bet on future production, not a write-down.Despite the negative performance reflected on GEM 63XL and SAW in the quarter, we are confident in our team's ability to complete qualification, and successfully deliver these products.
The Real Growth Engines
What the market may be missing is the breadth of the demand picture. International orders are accelerating – FMS cases are being approved faster, and the Middle East is a live market for IBCS. The company just qualified on the PAC 3 program and signed a $2 billion framework agreement with the Department of War and Lockheed Martin. As Warden said: “We have production capacity, and we are starting to build, and we are doing that even ahead of definitized contracts later this year.” — Kathy J. Warden, Chair, CEO and President · 2026-07-21 That ties into a broader production program pipeline that now includes ten multiyear agreements for missile acceleration. Meanwhile, the company's GEM 63XL program, despite its charge, is backed by a long-term National Security space buildout – that segment alone is expected to grow high single digits this year.
This isn't a new pivot – the strategy was laid out in prior quarters. Back in April, Warden said: “We are seeing an opportunity-rich environment.” — Kathy Warden, Chair, CEO and President · 2026-04-21 And in January, she emphasized: “We have been investing in our business to build capacity and capacity is critical to fielding capability quickly.” — Kathy Warden, Chair, CEO and President · 2026-01-27 That investment thesis is now paying off: record backlog, a raised EPS guide, and a first MRV launch scheduled for the day of the call.
Why the Tape Says the Opposite
The 90-day drawdown looks like a market overreaction to short-term noise. The company's fundamentals remain solid – the operating margin has been volatile quarter-to-quarter, but the long-term trend is upward as production programs mature. Free cash flow in Q2 was nearly $1 billion, and the company reaffirmed its 2026 cash flow guidance. The stock's decline may reflect broader concerns about defense valuations or a rotation out of the sector, but for Northrop specifically, the evidence points to acceleration, not deceleration. The market is pricing in a peak; the company's backlog suggests the opposite.